Noe LGA Gesundheit Thermenregion GmbH
- Address
- lock Available on a paid plan
Noe LGA Gesundheit Thermenregion GmbH - Cerebrovascular Disease Research
Noe LGA Gesundheit Thermenregion GmbH is a medical research center specializing in cerebrovascular disease investigation and stroke prevention strategies. The center focuses on evaluating novel therapeutic interventions for patients at high risk of recurrent ischemic events following acute cerebrovascular incidents.
- Secondary stroke prevention in non-cardioembolic ischemic stroke patients
- Transient ischemic attack (TIA) management and risk reduction
- Anticoagulation and antiplatelet therapy optimization
The center is actively engaged in phase III clinical trials investigating Factor XIa inhibitors as potential breakthrough therapies for stroke prevention. Their research emphasizes balancing efficacy in preventing ischemic stroke recurrence with safety considerations regarding major bleeding risk, particularly in patients receiving background antiplatelet therapy. This work contributes to advancing treatment options for individuals who have experienced acute non-cardioembolic ischemic stroke or high-risk transient ischemic attacks, populations with significant risk of subsequent cerebrovascular events.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Noe LGA Gesundheit Thermenregion GmbH
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Asundexian for Ischemic Stroke Prevention in Adults Post-Acute Non-Cardioembolic Stroke or High-Risk TIA | Bayer AG | Phase III | Not Recruiting | Jan 2023 | Oct 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Asundexian | 1 | Unknown | 2023-01-18 | 2023-01-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.